Loading...

ENSC ENSYSCE BIOSCIENCES INC Expansion Plans 8-K Filing

NSYS

NSC

ENSYSCE BIOSCIENCES INC

(ENSC)

2025 8-K

Financial Results Announcement

Board Resignation

Correction Filing

Delisting Notice

Annual Meeting Results

Funding Agreement Update

Financial Results Report

Financial Results Announced

Financial Statements

Equity Offerings

Filing Correction

Securities Offering

Financial Results

Stock Split Announcement

Annual Meeting Results

Financial Results

Bylaw Amendment

Financial Results

Compliance regained with Na...

Financial Results Announcement

Delisting Notice

Financial Results Announcement

Entry into Material Definit...

Postponed Meeting and Stock...

Postponement of Special Mee...

Financing Transaction

Financial Results Announcement

Financing Agreement

Financial Results Announcement

Compliance with Nasdaq List...

Listing Compliance

Public Offering

Change of Auditor

Financial Results Announcement

Reverse Stock Split

Special Meeting and Voting ...

Securities Purchase Agreement

Dividend Declaration

Delisting Notice

Investor Presentation

Financing Agreement

External Links:

Ensysce Biosciences has entered into a $10 million agreement with Galephar for the development and manufacturing of its PF614 drug, involving stock grants and milestone-based payments.

AI Assistant

ENSYSCE BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.